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Summary
 
Infection with HIV-1 requires expression of CD4 and the chemokine receptors CXCR4 or
CCR5 at the target cell surface. Engagement of these receptors by the HIV-1 envelope glyco-
protein is essential for membrane fusion, but may additionally activate intracellular signaling
pathways. In this study, we demonstrate that chemokines and HIV-1 envelope glycoproteins
from both T-tropic and macrophage-tropic strains rapidly induce tyrosine phosphorylation of
the protein tyrosine kinase Pyk2. The response requires CXCR4 and CCR5 to be accessible
on the cell surface. The results presented here provide the first evidence for activation of an in-
tracellular signaling event that can initiate multiple signaling pathways as a consequence of con-
tact between HIV-1 and chemokine receptors.
 
T
 
he chemokine receptors CCR5 and CXCR4 (also
called fusin or LESTR) serve as entry cofactors for
HIV (1). The viral strains that infect macrophages as well as
primary T cells (macrophage [M]-tropic viruses) use CCR5
as an entry cofactor, whereas viral strains that infect trans-
formed CD4
 
1
 
 cell lines as well as primary T cells (labora-
tory-adapted or T-tropic viruses) use CXCR4. HIV entry
is mediated by CD4-dependent interactions between the
surface subunit of the envelope glycoprotein (gp120) and
the chemokine receptors. Such interactions are thought to
result in exposure of the fusion domain of the transmem-
brane envelope glycoprotein subunit (gp41) and in subse-
quent viral entry (2). Viral preference for CCR5 versus
CXCR4 undergoes a characteristic change during the
course of infection and disease progression. Infection is ini-
tiated by M-tropic viruses and generally requires CCR5, as
indicated by the resistance of CCR5-null individuals to
HIV infection (3). The decline in immune system function
coincides with the appearance of viruses with broader tro-
pism, characterized by their ability to use CXCR4 and of-
ten additional chemokine receptors (4). The change in tro-
pism from CCR5 to CXCR4 suggests that there is
selection for usage of different coreceptors depending on
the stage of disease. Numerous factors may contribute to
this selection, including the distribution of chemokine re-
ceptors in different tissues, the regulation of receptor avail-
ability on the cell surface, and the effect of receptor en-
gagement on the physiological state of the cell. To begin
assessing the effect of envelope–receptor interactions on cell
physiology and HIV dissemination, we evaluated the ability
of HIV envelope glycoproteins to initiate intracellular sig-
nals through contact with CXCR4 and CCR5.
 
Materials and Methods
 
Cell Culture.
 
The growth medium for the cell lines was
RPMI supplemented with 2 mM glutamine, penicillin (100 U/ml),
streptomycin (100 
 
m
 
g/ml), 1 mM sodium pyruvate, 1% nones-
sential amino acids (all from GIBCO BRL, Bethesda, MD), and
10% FCS (Hyclone, Logan, UT). For cultures of HL60, the growth
medium was supplemented with 50 
 
m
 
M 2-mercaptoethanol
(Fisher Scientific Co., Pittsburgh, PA). DU6 is a CD4
 
1
 
 T cell
line specific for PPD (purified protein derivative of mycobacteria)
that was established from an uninfected donor. The EU2 T cell
line was generated from the PBMC of a CCR5-null HIV ex-
posed uninfected individual (designated EU2 in Liu et al., refer-
ence 5). CD8
 
1
 
 T cells were removed by magnetic bead sorting
(Dynal Inc., Lake Success, NY). The CD8-depleted lymphocytes
were then activated with 5 
 
m
 
g/ml PHA (Sigma Chemical Co.,
St. Louis, MO) and 100 U/ml human IL-2 (Chiron Corp., Em-
eryville, CA). Both T cell lines were periodically restimulated ev-
ery 12–16 d using 5 
 
m
 
g/ml PHA and allogeneic PBMC (10
 
6
 
/ml)
treated with 50 
 
m
 
g/ml mitomycin C (Sigma Chemical Co.) for
30 min at 37
 
8
 
C. Cells were then expanded and maintained in
growth medium with 100 U/ml human IL-2. DU6 and EU2
were maintained in culture for 2–4 mo, and for each assay were
used at least 13 d after the previous activation.
 
Reagents.
 
RANTES (regulated on activation normal T cell ex-
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pressed and secreted) and macrophage inhibitory protein (MIP)-1
 
b
 
were purchased from R & D Systems (Minneapolis, MN). SDF
(stromal cell–derived factor)-1
 
a
 
 was synthesized by native chemical
ligation as previously described (6) and has activity comparable to
native SDF-1
 
a
 
 (Siani, M.A., and D.A. Thompson, unpublished
data). Soluble gp120 from the T-tropic BH10 and SF2 strains was
a gift of R. Sweet (SmithKline Beecham, King of Prussia, PA;
reference 7). Soluble gp120/gp41 JRFL oligomeric complexes
were prepared as previously described (8). The anti-CXCR4
monoclonal antibody 12G5 (mouse IgG2a) was supplied by J.
Hoxie (University of Pennsylvania, Philadelphia, PA) and used at
50 
 
m
 
g/ml. The anti-CD8 monoclonal antibody (Leu2, mouse
IgG1) was purchased from Becton Dickinson (San Jose, CA), dia-
lyzed against PBS overnight at 4
 
8
 
C to remove sodium azide, and
used at saturation (1:3 dilution). Pertussis toxin was from List Bi-
ologicals (Campbell, CA).
 
Stimulation of Pyk2 Phosphorylation by Chemokine or HIV-1
Env.
 
20–48 h before the mixing experiments, HL60 cells were
transferred to growth medium with 0.5% FCS to lower the basal
level of Pyk2 activation. The T cell lines were kept in regular
growth medium until the time of the experiment. For the pertus-
sis toxin inhibition experiments, HL60 cells were treated with
pertussis toxin at 100 ng/ml for 20 h before treatment with enve-
lope or chemokine. 4 
 
3
 
 10
 
6
 
 HL60 cells or 0.5–1.5 
 
3
 
 10
 
7
 
 T cells
were resuspended in 0.1 ml growth medium/0.5% FCS. The
cells were kept at 37
 
8
 
C for 15 min before treatment. In the anti-
body blocking experiments, the cells were treated with antibody
at the start of the 15 min incubation. Chemokines or 293T trans-
fectants were added to the target cells in an equal volume of
growth medium/0.5% FCS. Cell lysis, immunoprecipitation, and
immunoblotting were performed as previously described (9).
 
Generation of 293T Cells Expressing HIV-1 Envelope Proteins.
 
293T cells were transiently transfected by calcium phosphate co-
precipitation as previously described (10). Expression vectors en-
coding gp120/gp41 from HXB2 or JRFL strains, or an empty ex-
pression vector, were cotransfected with pRev, encoding HIV-1
Rev (11), and phGFP-S65T (Clontech, Palo Alto, CA), encod-
ing green fluorescent protein. On average 30–40% of the trans-
fected cells were green fluorescent protein–positive. The level of
envelope expression was determined by flow cytometry or West-
ern blotting (Davis, C.B., unpublished data). The transfected cells
were harvested 48 h after transfection using 0.6 mM EDTA/PBS
plus brief trypsinization, and resuspended at 2–4 
 
3
 
 10
 
7
 
/ml. 1–4 
 
3
 
10
 
6
 
 cells in 0.1 ml were used for the mixing experiments.
 
Preparation of Pseudotyped HIV–luciferase Virus.
 
HIV–luciferase
(HIV–luc) reporter virions pseudotyped with JRFL or vesicular
stomatitis virus–G envelopes were generated according to Con-
nor et al. (12). 293T cells were transfected by calcium phosphate
coprecipitation with HIV–luc provirus and plasmids encoding
one of the two envelopes. Virus was harvested 48–60 h after
transfection. The JRFL-pseudotyped virions were concentrated
fivefold on a Minitan
 
“
 
-S filtration system (Millipore Corp., Bed-
ford, MA). p24 levels of the virion preparations were determined
by ELISA (Cellular Products, Inc., Buffalo, NY). Pseudotyped
virions were prepared at a final concentration of 5 
 
m
 
g p24/ml. 1
ml of virus was added to 5 
 
3
 
 10
 
6
 
 cells in 50 
 
m
 
l and the mixture was
incubated at 37
 
8
 
C for 90 s before lysis.
 
Results and Discussion
 
Binding of chemokines to their cognate receptors is of-
ten assayed by measuring calcium mobilization (13). Treat-
ment of several CD4
 
1
 
 cell lines with HIV-1 envelope
failed to trigger a calcium response, even though such re-
sponses could be elicited by chemokines (Davis, C.B., un-
published data). Since chemokine receptor stimulation can
have biological effects in the absence of measurable calcium
mobilization (14), we searched for other signaling mole-
cules that could be positioned downstream of the chemo-
kine receptors. Pyk2 is a protein tyrosine kinase, related to
p125-FAK, and is expressed primarily in cells of the neu-
ronal and hematopoietic lineages (15). Pyk2 is phosphory-
lated on tyrosine after ligand binding to G protein–coupled
receptors or treatment with agents that elevate intracellular
Ca
 
2
 
1
 
 concentration (9, 15). Tyrosine phosphorylation of Pyk2
in turn leads to stimulation of kinase activity and phosphor-
ylation of exogenous substrates (9, 15). Since CXCR4 and
CCR5 are G protein–coupled receptors, we examined the
possibility that their ligands could activate Pyk2. Human
promyelocytic leukemia cells (HL60) or CD4
 
1
 
 T cells (DU6)
were treated with the following chemokines: RANTES,
which binds primarily to CCR1, CCR4, and CCR5;
MIP-1
 
b
 
, which binds to CCR5; and SDF-1
 
a
 
, which binds
to CXCR4 (13). RANTES and SDF-1
 
a
 
, but not MIP-1
 
b
 
,
rapidly induced Pyk2 phosphorylation in HL60 cells (Fig.
1, 
 
a
 
 and 
 
b
 
, and Dikic, I., unpublished data). The response
peaked at 
 
z
 
30 s and had declined to basal levels by 5 min.
Pretreatment of HL60 cells with pertussis toxin ablated the
Pyk2 response, suggesting that Pyk2 phosphorylation is
mediated via G
 
i
 
 proteins (Fig. 1, 
 
a 
 
and
 
 b
 
) (16). The
RANTES effect is probably mediated through CCR1 or
CCR4, since HL60 cells failed to mobilize calcium to
MIP-1
 
b
 
 (Davis, C.B., unpublished data), consistent with
the lack of CCR5. In contrast, the DU6 cell line did mobi-
lize calcium in response to MIP-1
 
b
 
 (Davis, C.B., unpub-
lished data), indicating expression of CCR5. Indeed, MIP-
1
 
b
 
, as well as RANTES and SDF-1
 
a
 
, induced Pyk2 phos-
phorylation in DU6 cells with kinetics comparable to those
in HL60 cells (Fig. 1 
 
c
 
).
The CCR5 ligands RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
can block infection by M-tropic HIV-1 strains (17), and
the CXCR4 ligand SDF-1
 
a
 
 can block infection by T-tropic
strains (18, 19). Conversely, HIV envelopes can compete
with the corresponding chemokines for binding to their re-
ceptors (8, 20, 21). The overlap between binding sites for
chemokine and envelope suggests that envelope engage-
ment of the chemokine receptor may mediate a signal sim-
ilar to that of the physiological ligand. We therefore tested
whether tyrosine phosphorylation of Pyk2 could be trig-
gered by HIV-1 envelope glycoproteins.
We first determined whether HIV-1 envelope glycopro-
tein expressed on the surface of 293T cells could trigger
Pyk2 phosphorylation in cells expressing the appropriate
chemokine receptor. The 293T cells, which do not express
Pyk2 (9, 15), were transfected with HIV-1 envelope ex-
pression constructs encoding the T-tropic HXB2 or the
M-tropic JRFL envelope glycoproteins (22, 23). These cells
were then mixed with HL60 cells, which can fuse with en-
velopes from T-tropic but not M-tropic HIV-1 strains (24),
or DU6, which can be infected by both T-tropic and 
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M-tropic HIV-1 strains (Davis, C.B., unpublished data).
Tyrosine phosphorylation of Pyk2 was observed when
HL60 cells were mixed with 293T transfectants expressing
the HXB2, but not the JRFL, envelope glycoprotein (Fig.
2 
 
a
 
, 
 
left
 
). In contrast, DU6 cells showed increased tyrosine
phosphorylated Pyk2 when mixed with transfectants ex-
pressing  either HXB2 or JRFL envelope glycoprotein (Fig. 2
 
a
 
, 
 
right
 
). To test whether cell contact with HIV-1 virions
triggers phosphorylation of Pyk2, we made use of a system in
which envelope-deficient HIV–luc reporter viruses can be
coated with different viral envelopes (12). HIV–luc particles
coated with JRFL envelope glycoprotein were mixed with
DU6 T cells and analyzed for the status of Pyk2 phosphor-
ylation (Fig. 2 
 
b
 
).
 
 
 
As a control for nonspecific effects medi-
ated by HIV–luc viral particles, DU6 cells were also mixed
with HIV–luc coated with the VSV-G envelope, which
mediates infection of cells via binding to sialic acid residues
(25). HIV–luc coated with JRFL, but not with VSV-G,
could induce tyrosine phosphorylation of Pyk2 (Fig. 2 
 
b
 
).
Overall, these results indicate that Pyk2 is tyrosine phos-
phorylated when uninfected cells encounter envelope on
the surface of virions or infected cells.
To further characterize the pathway leading to Pyk2 ty-
rosine phosphorylation after binding of T-tropic envelope
to HL60, these cells were treated with a soluble mono-
meric form of the gp120 subunit from the BH10 clone of
the T-tropic IIIB strain (26). Tyrosine phosphorylation of
Pyk2 was readily detected after addition of BH10 gp120,
with kinetics similar to those observed after treatment with
the chemokines SDF-1
 
a
 
 and RANTES (Fig. 3 
 
a
 
, compare
with Fig. 1, 
 
a
 
 and 
 
b
 
). Gp120 is thus sufficient to stimulate
Pyk2 phosphorylation, and other molecules contributed by
the 293T transfectants are not required. In addition, the
Pyk2 response to monomeric gp120 suggests that receptor
cross-linking is not required. The Pyk2 response to BH10
gp120 was inhibitable with pertussis toxin (Fig. 3 
 
a
 
), impli-
cating G
 
i
 
-linked pathways in the response to either SDF-1
 
a
 
or HIV envelope glycoprotein in these cells.
T-tropic HIV gp120 binds to both CD4 (7) and CXCR4
(21, 27). HIV gp120 binding to CD4 has been reported to
transduce signals that are dependent on the CD4 cytoplas-
mic domain (28, 29). Therefore, Pyk2 phosphorylation
could be triggered by gp120 binding to CXCR4, CD4, or
both. To confirm that Pyk2 phosphorylation induced by
Figure 1. Tyrosine phosphorylation of Pyk2 in response to chemokines. (a and b) HL60 promyelocytic leukemia cells were incubated with 500 nM
RANTES (a) or SDF-1a (b) at 378C for the indicated times before lysis. (1PTx) Cells were pretreated with pertussis toxin before incubation with
chemokines. Pyk2 was immunoprecipitated (IP) with rabbit antibodies against Pyk2 and blotted with antiphosphotyrosine (anti-PTyr) or anti-Pyk2 anti-
bodies. (c) DU6 CD41 T cells were incubated with RANTES, MIP-1b, or SDF-1a (500 nM each) for the indicated times before lysis and processing as
in a and b.
Figure 2. Tyrosine phosphorylation of Pyk2 after contact with HIV-1
envelope glycoprotein on the surface of transfected 293T cells and viri-
ons. (a) HL60 or DU6 cells were lysed 30 s after being mixed with 293T
cells expressing M-tropic (JRFL), T-tropic (HXB2), or no (2) envelope.
(b) DU6 cells were mixed with HIV–luc particles pseudotyped with ei-
ther JRFL or VSV-G envelopes and lysed after 90 s. As a positive control,
MIP-1b was incubated with DU6 cells for 30 s before lysis.
Figure 3. Tyrosine phosphorylation of Pyk2 mediated by T-tropic
gp120 can be inhibited by pertussis toxin or a monoclonal antibody
against CXCR4. (a) HL60 cells were pretreated with pertussis toxin or
left untreated. Treated and untreated cells were incubated with T-tropic
gp120 (BH10, 5 mg/ml) for the indicated times before lysis. (b) HL60
cells were resuspended in growth media/0.5% FCS either without anti-
body (no Ab) or containing monoclonal antibodies specific for CXCR4
(anti-CXCR4) or human CD8 (control Ab). Cells were incubated with an-
tibody at 378C for 15 min, then mixed with T-tropic SF-2 envelope for
30 s before lysis.1796 Signal Transduction Induced by HIV-1 Envelope
T-tropic envelope requires CXCR4, HL60 cells were pre-
treated with a monoclonal antibody against CXCR4 that
blocks T-tropic gp120 binding to CXCR4 and inhibits in-
fection by CXCR4-tropic strains of HIV-1 and HIV-2
(21, 30). Pretreatment with this monoclonal antibody atten-
uated the Pyk2 response to gp120 from BH10 and a T-tro-
pic  virus, SF-2 (31; Fig. 3 b; and our unpublished data).
CXCR4 thus must be accessible to gp120 and associated
with functional G protein for Pyk2 to be activated and ty-
rosine phosphorylated.
To determine whether CCR5 is required for signaling
after binding of M-tropic envelope glycoprotein, Pyk2 ty-
rosine phosphorylation was compared in wild-type and
CCR52 T cell lines. The mutant cell line was derived from
an HIV-1 exposed uninfected patient (EU2) who is homo-
zygous for a 32-bp deletion in the CCR5 coding sequence
and lacks cell surface expression of CCR5. The EU2 cell
line fails to display calcium mobilization or chemotaxis in
response to MIP-1b treatment, and is resistant to M-tropic
HIV-1 infection (5; Davis, C.B., unpublished data). DU6
and EU2 cells were treated with MIP-1b, SDF-1a, or sol-
uble oligomerized JRFL gp120/gp41. Pyk2 was strongly
phosphorylated in DU6 cells treated with either MIP-1b
or JRFL envelope glycoprotein (Fig. 4, left). EU2 cells, in
contrast, failed to respond to either stimulus, but responded
to SDF-1a, indicating that the signaling pathway between
CXCR4 and Pyk2 is intact (Fig. 4, right). Overall, these
data indicate that CD4 engagement alone is insufficient for
activation of Pyk2 via M-tropic envelope and that CCR5
must be available on the cell surface.
The activation of signal transduction pathways by HIV-1
envelope glycoprotein binding to chemokine receptors raises
several interesting questions regarding the role of signaling
in HIV pathogenesis. Viral entry does not depend on Gi-
coupled signaling (32), and mutations in CCR5 that ablate
signal transduction do not affect coreceptor activity (33). G
protein–linked signaling thus may be simply a by-product
of envelope engagement of chemokine receptors. However,
triggering of chemokine signaling cascades in vivo may pre-
pare the target cells for viral replication and may be respon-
sible for some of the cellular responses to the virus. For ex-
ample, specific sequences in the envelope glycoprotein have
been shown to direct not only envelope fusion, but also
events in the intracellular viral life cycle after fusion (34).
Differences in signaling pathways may also explain the dif-
ferential use of chemokine receptors by strains of HIV-1
during the course of infection. It has been shown that Pyk2
can be activated in response to a variety of extracellular
stimuli and that activated Pyk2 can feed into the MAP ki-
nase or JUN kinase signaling pathways in different cell types
(9, 15, 35). Moreover, activation of Pyk2 by extracellular
stimulation also leads to tyrosine phosphorylation and mod-
ulation of ion channel function (15). Pyk2 is therefore able
to provide a potential link between HIV binding to
chemokine receptors and several intracellular pathways that
regulate cell growth, cell survival, and cell differentiation.
In addition, ligand binding to chemokine receptors has been
shown to induce alterations in cytoskeletal structure and
cell adhesion (13) that, in the case of HIV infection, may
facilitate viral transmission from infected to uninfected
cells. Elucidation of the role of these intracellular events
will require in vivo models in which candidate signaling
pathways can be specifically manipulated over the course of
infection.
Figure 4. Tyrosine phosphorylation of Pyk2 in response to M-tropic
gp120/gp41 requires expression of CCR5 on target cells. DU6 cells (5 3
106) or the equivalent number of CD41CCR52 T cells (EU2) were incu-
bated with MIP-1b (500 nM), SDF-1a (500 nM), or JRFL gp120/gp41
(5 mg/ml) for 30 s before lysis.
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